{"id":"top2a","name":"Topoisomerase II alpha (TOP2A)","symbol":"TOP2A","route":"/targets/top2a/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11989","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131747","uniprot":"https://www.uniprot.org/uniprotkb/P11388/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P11388","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1806","open-targets":"https://platform.opentargets.org/target/ENSG00000131747","civic":"https://civicdb.org/genes/7153/summary","oncokb":"https://www.oncokb.org/gene/TOP2A","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TOP2A","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=TOP2A","depmap":"https://depmap.org/portal/gene/TOP2A?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000131747-TOP2A","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/7153","omim":"https://www.omim.org/entry/126430"}],"products":[{"id":"aldoxorubicin","name":"Aldoxorubicin","status":"phase-3","modality":"Albumin-binding small-molecule prodrug of doxorubicin, intravenous","route":"/drugs/aldoxorubicin/"},{"id":"amrubicin","name":"Amrubicin","status":"established","modality":"Synthetic anthracycline (topoisomerase II inhibitor), intravenous","route":"/drugs/amrubicin/"},{"id":"amsacrine","name":"Amsacrine","status":"established","modality":"Acridine topoisomerase II inhibitor, intravenous","route":"/drugs/amsacrine/"},{"id":"pirarubicin","name":"Pirarubicin","status":"established","modality":"Anthracycline (topoisomerase II inhibitor), intravenous or intravesical","route":"/drugs/pirarubicin/"},{"id":"pixantrone","name":"Pixantrone","status":"withdrawn","modality":"Aza-anthracenedione cytotoxic, intravenous","route":"/drugs/pixantrone/"},{"id":"teniposide","name":"Teniposide","status":"established","modality":"Podophyllotoxin topoisomerase II inhibitor, intravenous","route":"/drugs/teniposide/"}],"trials":[{"id":"dellphi-304","name":"DeLLphi-304","nct":"NCT05740566","phase":"3","status":"positive"},{"id":"nct07424287","name":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","nct":"NCT07424287","phase":"3","status":"recruiting"},{"id":"aldoxorubicin-phase-3-sts","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","nct":"NCT02049905","phase":"3","status":"negative"},{"id":"nct00003436","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia","nct":"NCT00003436","phase":"3","status":"completed"},{"id":"nct00002719","name":"Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia","nct":"NCT00002719","phase":"3","status":"completed"},{"id":"nct00002658","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","nct":"NCT00002658","phase":"3"},{"id":"ideate-lung02","name":"IDeate-Lung02","nct":"NCT06203210","phase":"3","status":"recruiting"},{"id":"nct06801834","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","nct":"NCT06801834","phase":"3","status":"recruiting"},{"id":"nct01700946","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","nct":"NCT01700946","phase":"2","status":"completed"},{"id":"nct01086605","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","nct":"NCT01086605","phase":"2","status":"completed"},{"id":"nct04437160","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","nct":"NCT04437160","phase":"2","status":"recruiting"},{"id":"nct04390399","name":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","nct":"NCT04390399","phase":"2","status":"active"},{"id":"nct03458260","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","nct":"NCT03458260","phase":"2","status":"completed"},{"id":"nct07583511","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","nct":"NCT07583511","phase":"2","status":"recruiting"},{"id":"nct07188441","name":"Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin","nct":"NCT07188441","phase":"2","status":"recruiting"}],"pathways":[],"companies":["bms","gemini-therapeutics","immunitybio","nippon-kayaku","servier","sumitomo-pharma"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}